Explore

Rapid Read Rapid Read
Massive Bio and Optellum Partner to Enhance Clinical Trial Access for Lung Cancer Patients

Massive Bio and Optellum Partner to Enhance Clinical Trial Access for Lung Cancer Patients

Massive Bio, a leader in AI-driven precision oncology, and Optellum, known for AI-enabled lung cancer diagnosis, have announced a collaboration aimed at improving clinical trial access for patients with early-stage non-small cell lung cancer (NSCLC). This partnership integrates Optellum's Lung Cancer Prediction AI, which identifies high-risk lung nodule patients, with Massive Bio's clinical trial matching platform. The goal is to ensure that patients identified as high-risk through routine imaging are promptly considered for clinical trials, potentially expanding their treatment options. This initiative addresses a significant gap in oncology, where many high-risk patients do not reach clinical trials due to delays in referral processes.
Rapid Read Rapid Read
Legend Biotech's CAR T Therapy Shows 100% Response Rate in Lymphoma Study

Legend Biotech's CAR T Therapy Shows 100% Response Rate in Lymphoma Study

Legend Biotech's CAR T therapy, LB2501, has achieved a 100% response rate in a Phase 1 study of non-Hodgkin lymphoma. All six patients treated with the therapy responded, with five achieving complete remission. The study's results position Legend Biotech as a potential takeover target in the competitive CAR T market. The therapy demonstrated a favorable safety profile, with no dose-limiting toxicities or serious adverse events reported. The trial is ongoing, with further data expected in the coming years.
Reuters Reuters
'It's still working': More are living with cancer as era of targeted drugs takes hold

'It's still working': More are living with cancer as era of targeted drugs takes hold

By Deena Beasley June 3 (Reuters) - Cathy Smithwick, now 67, has lived with breast cancer, and then ovarian cancer, for more than 20 years with the help of targeted drugs, drugs that harness the body's immune system, chemotherapy and hormone pills.
Trendline Trendline
Noah Medical Appoints Dr. Krish Bhadra as Chief Pulmonary Advisor to Enhance Lung Cancer Diagnosis

Noah Medical Appoints Dr. Krish Bhadra as Chief Pulmonary Advisor to Enhance Lung Cancer Diagnosis

Noah Medical Appoints Dr. Krish Bhadra as Chief Pulmonary Advisor to Enhance Lung Cancer Diagnosis
Rapid Read Rapid Read
Melanoma Research Alliance Appoints Stephanie Kauffman as CEO Amidst Research Advancements

Melanoma Research Alliance Appoints Stephanie Kauffman as CEO Amidst Research Advancements

The Melanoma Research Alliance (MRA) has appointed Stephanie Kauffman as its new Chief Executive Officer, effective July 1, 2026. Kauffman succeeds Marc Hurlbert, who will lead the National Kidney Foundation. Under Kauffman's leadership, MRA aims to accelerate melanoma research through strategic collaborations and investments in artificial intelligence, precision medicine, and immunotherapy. The organization has invested over $200 million in research since its inception, contributing to significant therapeutic advancements. Kauffman, previously MRA's President and COO, is poised to lead the organization into a new era of scientific breakthroughs.
Trendline Trendline
Tempus Reveals Multimodal Foundation Model Results for Oncology Insights

Tempus Reveals Multimodal Foundation Model Results for Oncology Insights

Tempus Reveals Multimodal Foundation Model Results for Oncology Insights
Rapid Read Rapid Read
D3 Bio's KRAS G12C Inhibitor Shows Promising Results in NSCLC

D3 Bio's KRAS G12C Inhibitor Shows Promising Results in NSCLC

D3 Bio has presented first-line clinical data for elisrasib, a next-generation KRAS G12C inhibitor, at the 2026 ASCO Annual Meeting. The study showed that elisrasib, both as a monotherapy and in combination with pembrolizumab, demonstrated high efficacy in patients with KRAS G12C mutation-positive non-small cell lung cancer (NSCLC). The monotherapy achieved a 78% overall response rate, while the combination therapy reached an 81.3% response rate, indicating strong antitumor activity across all PD-L1 expression levels.
Trendline Trendline
Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment

Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment

Kelun-Biotech's Lunbotinib Fumarate Shows Promising Results in Lung Cancer Treatment
Rapid Read Rapid Read
Innovent's IBI363 Shows Promising Results in Immunotherapy-Resistant Lung Cancer

Innovent's IBI363 Shows Promising Results in Immunotherapy-Resistant Lung Cancer

Innovent Biologics presented updated data from their Phase 1 proof-of-concept study of IBI363, a PD-1/IL-2α-bias bispecific fusion protein, at the 2026 American Society of Clinical Oncology Annual Meeting. The study focused on patients with advanced immunotherapy-resistant non-small cell lung cancer (NSCLC). IBI363 demonstrated robust survival benefits, with a median progression-free survival (PFS) of 10.1 months and a median overall survival (OS) of 18.2 months in squamous NSCLC patients. The study also highlighted the potential for long-term survival benefits in patients with a smoking history. IBI363 is currently being evaluated in a global Phase 3 clinical study for IO-resistant squamous NSCLC.
Trendline Trendline
Salubris Biotherapeutics Presents Promising Phase 1/2 Data for JK06 at ASCO 2026

Salubris Biotherapeutics Presents Promising Phase 1/2 Data for JK06 at ASCO 2026

Salubris Biotherapeutics Presents Promising Phase 1/2 Data for JK06 at ASCO 2026
Trendline Trendline
Hummingbird Diagnostics Unveils New Lung Cancer Biomarker Findings at EACR

Hummingbird Diagnostics Unveils New Lung Cancer Biomarker Findings at EACR

Hummingbird Diagnostics Unveils New Lung Cancer Biomarker Findings at EACR
Rapid Read Rapid Read
Summit Therapeutics Faces Challenges with Ivonescimab Data at ASCO

Summit Therapeutics Faces Challenges with Ivonescimab Data at ASCO

Summit Therapeutics presented data on ivonescimab at the ASCO annual meeting, showing a 34% reduction in the risk of death in a Phase 3 lung cancer trial in Chinese patients. However, questions remain about the drug's efficacy in a more diverse U.S. population. The trial showed a four-month overall survival benefit, but the population was primarily young Chinese men with lung cancer who had smoked. Analysts are cautious about the drug's potential benefit in a global population, and Summit faces pressure to replicate the results in a broader Phase 3 trial.